


RESEARCH ARTICLE

Inventory study of an early pandemic COVID-19 cohort in South-Eastern Sweden, focusing on neurological manifestations

Doryaneh Ahmadpour^{1,2}, Anna Kristoffersson², Mats Fredrikson³, Yumin Huang-Link⁴, Anne Eriksson⁵, Ellen Iacobaeus⁶, Anne-Marie Landtblom^{4,7}, Sara Haghighi^{2,4*}

1 Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden, **2** Department of Medical Specialists, Institute of Neurology, Motala Hospital, Motala, Sweden, **3** Forum Östergötland, Linköping University, Linköping, Sweden, **4** Department of Neurology, Linköping University Hospital, Linköping, Sweden, **5** Department of Medical Specialists, Institute of Medicine, Motala Hospital, Motala, Sweden, **6** Division of Neurology, Department of Clinical Neuroscience, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, **7** Department of Medical Sciences, Uppsala University, Uppsala, Sweden

* Sara.Haghighi.Mobarhan.Smith@regionostergotland.se



OPEN ACCESS

Citation: Ahmadpour D, Kristoffersson A, Fredrikson M, Huang-Link Y, Eriksson A, Iacobaeus E, et al. (2023) Inventory study of an early pandemic COVID-19 cohort in South-Eastern Sweden, focusing on neurological manifestations. *PLoS ONE* 18(1): e0280376. <https://doi.org/10.1371/journal.pone.0280376>

Editor: Marta A. Kisiel, Uppsala Universitet, SWEDEN

Received: October 20, 2022

Accepted: December 27, 2022

Published: January 13, 2023

Copyright: © 2023 Ahmadpour et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: It is not possible to share a minimal data set for ethical and legal reasons. In accord with the Swedish legislation on research ethics, the study participants were guaranteed that the data only would be available to, and managed by the researchers. This condition was approved by the Swedish Research Ethics Authority. Consequently, researchers who meet the criteria to access confidential information, and who have acquired ethical approval to do so, may

Abstract

Background

Neurological manifestations in patients with COVID-19 have been reported previously as outcomes of the infection.

The purpose of current study was to investigate the occurrence of neurological signs and symptoms in COVID-19 patients, in the county of Östergötland in southeastern Sweden.

Methods

This is a retrospective, observational cohort study. Data were collected between March 2020 and June 2020. Information was extracted from medical records by a trained research assistant and physician and all data were validated by a senior neurologist.

Results

Seventy-four percent of patients developed at least one neurological symptom during the acute phase of the infection. Headache (43%) was the most common neurological symptom, followed by anosmia and/or ageusia (33%), confusion (28%), hallucinations (17%), dizziness (16%), sleep disorders in terms of insomnia and OSAS (Obstructive Sleep Apnea) (9%), myopathy and neuropathy (8%) and numbness and tingling (5%). Patients treated in the ICU had a higher male presentation (73%). Several risk factors in terms of co-morbidities, were identified. Hypertension (54.5%), depression and anxiety (51%), sleep disorders in terms of insomnia and OSAS (30%), cardiovascular morbidity (28%), autoimmune diseases (25%), chronic lung diseases (24%) and diabetes mellitus type 2 (23%) founded as possible risk factors.

request the data by contacting the registrar (registrator@regionostergotland.se).

Funding: The author(s) received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Conclusion

Neurological symptoms were found in the vast majority (74%) of the patients. Accordingly, attention to neurological, mental and sleep disturbances is warranted with involvement of neurological expertise, in order to avoid further complications and long-term neurological effect of COVID-19. Furthermore, risk factors for more severe COVID-19, in terms of possible co-morbidities that identified in this study should get appropriate attention to optimizing treatment strategies in COVID-19 patients.

Introduction

Coronaviruses are a large family of viruses causing disease in many species including humans. The first identified severe disease in humans caused by coronaviruses was Severe Acute Respiratory syndrome (SARS) emerging in 2002 with a 9.5% mortality rate, followed by Middle East Respiratory Syndrome [1–3] emerging in 2012 with a 34.4% mortality rate [4, 5]. The latest severe disease caused by coronaviruses reported first in Wuhan, China in December 2019 caused severe acute respiratory disease COVID-19 [6]. The most common symptoms of SARS-CoV-2 infection are fever, cough, fatigue, shortness of breath, and muscle soreness [7]. Rhinorrhea, chest tightness, sore throat, nausea, vomiting, diarrhea, headache, ageusia, and anosmia have also commonly been reported among infected persons [8]. While some patients only experience a mild fever, mild fatigue, or even no symptoms [9, 10], severe illness with acute respiratory distress syndrome, respiratory failure, multiple organ failure and death has occurred in other patients [11].

Previous studies addressed the association of obesity and age with COVID-19 severity and poor prognosis [12, 13]. Underlying comorbidities such as cardiovascular disease, hypertension, diabetes, and renal disease are also associated with detrimental outcomes [14, 15]. In addition, neurological manifestations related to COVID-19 have been reported. Fatigue, myalgia, anosmia, ageusia and headache are common neurologic symptoms observed in COVID-19 patients. Dizziness, acute confusion/delirium, agitation, stroke, hypoxic ischemic injury, seizures, coma, and encephalitis have also been reported [16–19].

Here we present a retrospective, observational cohort on data collected from March -June 2020 at two medical centers in Östergötland County, Sweden including 196 consecutive patients with laboratory confirmed diagnosis of COVID-19.

Materials and methods

Study population

A total of 690 patients were diagnosed with COVID-19 during March 2020 to June 2020 in Östergötland county, including 68 patients at Motala Hospital, and 522 patients from other parts of the county. All adult patients (>18 years) with COVID-19 regardless of if they were treated as outpatients or inpatients with COVID-19 as a primary diagnosis or co-diagnosis, were retrospectively identified through a local diagnosis registry. Patients with negative PCR, deceased patients, presence of protected personal data or a diagnosis of frontal lobe dementia were excluded which resulted in 434 patients eligible for inclusion in the study. We sent a letter to 434 COVID-19 patients (384 patients from Medicine center and 50 patients from Motala Hospital) with information about the aims of study and study procedure and all patients provided informed written consent to have data from their medical records in research. We

received 197 consent letters (signed the informed consent) and 196 patients were included in the current study after fulfilling inclusion criteria (Fig 1). All data were fully anonymized and all data handled in according to Data Protection ACT (Personal Data Act, 1998:204).

Demographic and clinical data including neurological symptoms of each study patients were extracted from electronic records by a trained research assistant and physician and collected data were checked by a senior neurologist through medical chart review. Neurological symptoms and signs were categorized as attributed to the central nervous system, peripheral nervous system, or musculoskeletal system.

Statistics

Mean and standard deviation were calculated for continuous variables (e.g., age) and were summarized using descriptive statistics. Categorical variables were summarized as absolute frequencies and percentages. The software used for statistical analysis was Stata v17.1, StataCorp LLC, College Station, USA.

Ethics statement

The Linköping Medical Ethics Committee gave their approval to the study (Dnr 2020–02591). The study was conducted in agreement with the declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013).

Results

Baseline demographics

A total number of 196 patients (105 /91 male vs female) with COVID-19 were enrolled during the study. The age of patients ranged from 25 to 92 years, with an average age of 62 years. Eighty-six patients out of 196 were over 65 years old. This population was predominantly Nordic European and the average BMI was 29,5. Ongoing or history of past smoking was reported in 57%, ongoing /past use of oral tobacco (snuff) was detected in 40% and 23% had a history of chronic alcohol overconsumption (Table 1).

The most common pre-existing and concurrent comorbidities found in the medical files were hypertension, depression and anxiety, sleep disorders in terms of insomnia and OSAS, cardio- or cerebrovascular disease, autoimmune diseases (S1 Table), chronic lung diseases mainly in form of Asthma and/or Chronic Obstructive Pulmonary Disease (COPD), diabetes mellitus type 2 and Allergic Rhinitis/Pollen allergy (Table 1).

Clinical COVID-19 related signs, symptoms and outcome

All COVID-19 related clinical manifestations are listed in Table 2.

The most common symptom was fever, followed by cough, need of oxygen supply, dyspnea, gastrointestinal symptoms and bacterial or fungal infections. Among 196 patients, 175 (89%) needed hospitalization during the COVID-19 infection with an average medical care period of 16 days and a mean time-period of 18 days in the Intensive Care Unit (ICU) (Table 2).

Among ICU patients, 33 (73%) versus 12 (27%) were male respective female with an average age of 62 (S2 Table). 82% of ICU patients were intubated. Cardiovascular disease as comorbidity were seen more often in ICU patients compared to non-ICU patients ($p < 0.005$). Otherwise, all demographic variables, including the frequency and type of co-morbidities, were comparable in the patients admitted to the ICU and the non-ICU patients. The duration of medical care at ICU had not any impact on disease severity.




Fig 1.

<https://doi.org/10.1371/journal.pone.0280376.g001>

Neurological manifestations

A total of 145 out of 196 patients (74%) developed at least one neurological symptom during hospitalization for COVID-19 (Table 3).

The most common neurological symptom was headache followed by anosmia and/or ageusia, confusion, hallucinations, dizziness, and disturbance of sleep in terms of insomnia and OSAS. Twelve patients (8%) experienced myopathy and/or neuropathy (Table 3), including three with clinical and electrophysiological verified critical illness polyneuropathy and myopathy among the ICU patients.

The presence of neurological symptoms overall and/or a specific neurological symptom did not correlate with COVID-19 severity with regard to duration of hospital stay and/or need of ICU care. Furthermore, none of the co-morbidities were correlated with occurrence of a specific neurological symptom or presence of neurological symptoms overall.

Discussion

This retrospective study on 196 symptomatic COVID-19 patients, revealed 145 patients (74%) with at least one neurological symptom such as headache, anosmia and/or ageusia. More severe neurological and mental complications such as confusion and hallucination were almost exclusively observed in mid-older patients (average age of 67).

Many other studies have also reported similar neurological symptoms of which the incidence of overall neurological manifestations has varied broadly from 36% [20] to 73% [21]. Another recent study reported a yet higher frequency, of 84% of neurological symptoms in

Table 1. Characteristics of the study patients.

| | n | Total known | % |
|---|------------|-------------|-----------|
| Age, mean (range) | 62 (25–92) | 196 | |
| ≥65 years old | 86 (43/43) | 196 | 44% |
| Sex (male/female) | 105/91 | 196 | 54%/46% |
| BMI, mean | 29,5 | 127 | |
| Ongoing/history of smoking | 87 | 152 | 57% |
| Ongoing/history of snuffing | 21 | 52 | 40% |
| Ongoing /history of alcohol overconsumption | 13 | 56 | 23% |
| Comorbidities | | | |
| Hypertension | 97 | 178 | 54.5% |
| Depression and anxiety | 81 | 160 | 51% |
| Sleep disorders (insomnia and/or OSAS) | 50 | 165 | 30% |
| Cardio- or cerebrovascular disease | 46 | 166 | 28% |
| Autoimmune disease | 39 | 156 | 25% |
| Chronic Lung disease (Asthma and/or COPD) | 38 (37) | 159 | 24% (23%) |
| Diabetes Mellitus type II | 38 | 164 | 23% |
| Allergic Rhinitis/Pollen allergy | 27 | 171 | 16% |
| Chronic kidney disease | 17 | 162 | 10.5% |
| Thromboembolic disease | 14 | 155 | 9% |
| Other psychiatric disorders | 5 | 156 | 3% |

Table 1 shows the overall demographics and comorbidities of study patients. “n” shows the number of patients who replied positive to the corresponding variable, “total known” represents the total number of patients who replied to the corresponding question and the column to the most right shows the percentage of occurrence of each variable in regard to the respective total known cases.

OSAS = Obstructive Sleep Apnea.

COPD = Chronic Obstructive Pulmonary Disease.

<https://doi.org/10.1371/journal.pone.0280376.t001>

Table 2. Overall symptoms under first and/or second medical care seek.

| Variable | n | Total known | % |
|--|-----|-------------|-------|
| Hospitalization | 175 | 196 | 89% |
| Average of medical care period (days) | 16 | | |
| Average of days in Intensive Care Unit (days) | 18 | | |
| General symptoms | | | |
| Fever | 177 | 184 | 96% |
| Cough | 167 | 184 | 91% |
| Oxygen supply requirement | 108 | 134 | 80% |
| Dyspnea/shortness of breath | 128 | 179 | 71.5% |
| Gastrointestinal symptoms (nausea, vomiting or diarrhea) | 94 | 181 | 52% |
| Bacterial or fungal infections | 59 | 160 | 37% |
| Respiratory care | 37 | 134 | 28% |
| Coagulation disorder | 17 | 188 | 9% |

Table 2 shows the symptoms during first and/or second medical care seek. “n” shows the number of patients who replied positive to the corresponding variable, “total known” represents the total number of patients who replied to the corresponding question and the column to the most right shows the percentage of occurrence of each variable in regard to the respective total known cases.

<https://doi.org/10.1371/journal.pone.0280376.t002>

Table 3. Neurological manifestations.

| Patients with neurological manifestations during COVID-19 | n = 145 (%) | % /196 |
|---|-------------|--------|
| Headache | 63 (43%) | 32% |
| Anosmia and/or ageusia | 48 (33%) | 23% |
| Confusion | 41 (28%) | 21% |
| Hallucination | 25 (17%) | 13% |
| Dizziness | 23 (16%) | 12% |
| Sleep disorders (insomnia & OSAS) | 13 (9%) | 7% |
| Myopathy and neuropathy | 12 (8%) | 6% |
| Numbness and tingling | 8 (5%) | 4% |

Table 3 shows different neurological manifestations among study population. The middle column shows the number of positive cases in regard to each variable and the percentage among total number of patients with neurological manifestation (n = 145). The column to the right shows the percentage among the total number of study patients (n = 196).

OSAS = Obstructive Sleep Apnea.

<https://doi.org/10.1371/journal.pone.0280376.t003>

COVID-19 infected individuals compared to the present study [22]. The high prevalence of neurological manifestations associated with COVID-19 is suggested to be either indirect consequence of thrombotic complication, inflammation, hypoxia, dysregulation of blood pressure, or a direct cause of neurotropic properties of the virus itself [23, 24]. However, more research needs to be performed to understand the pathogenic mechanisms behind neurological disorders.

Similar to our study, the most common neurological symptoms previously reported have been headache, anosmia and/or ageusia [25, 26]. In some studies, with severe cases, stroke, seizure, and encephalopathy has also been reported as neurological symptoms [27]. Moreover, although confusion and hallucination has been considered as atypical and unusual presentation of COVID-19 [28], many independent studies have described these symptoms as a recurrent neurologic manifestation of COVID-19 [29, 30]. In our study, 28% of the patients with neurological and mental manifestations showed confusion and 17% of patients experienced hallucination.

It is also acknowledged that certain underlying host factors and medical conditions pose a greater risk for a more severe COVID 19 disease course. Males have been reported to have a higher likelihood for more severe outcome of COVID-19 [31], which is in line with our study, showing that 73% of ICU patients were males (S2 Table). Previous studies have identified overweight and obesity as risk factors for COVID-19 associated hospitalization and death [32, 33], the risk for hospitalization and ICU admission was lowest among healthy BMIs (18.5–24.9 kg/m²) but dramatically increased with overweight (25–29.9 kg/m²) and obesity [33]. Interestingly and in line with previous studies, the mean BMI of the current COVID-19 cohort was 29.5 (Table 1). Several studies [25, 34–36] have reported hypertension as the most common comorbidity among COVID-19 patients and as a lead risk factor for developing severe COVID-19 [37], which has been suggested to be associated with upregulation of *ACE2* gene expression, encoding for the receptor used by SARS-CoV-2 [38, 39]. Here, our study also highlighted a broad spectrum of comorbidities in the COVID-19 patients, of which the most common comorbidity was hypertension (54.5%). Interestingly, the second most common comorbidity in the present COVID-19 patients was depression and anxiety (51%, Table 1). This is in line with several other studies highlighting the impact of pre-existing mental disorders and increased probability of developing COVID-19 [40–42].

We also observed a high incidence (30%) of sleep disturbance in terms of insomnia and OSAS among the preceding and concurrent comorbidities in the study cohort, which may indicate that such symptoms are a risk factor to consider (Table 1). The frequency of insomnia in our material is not different from the expected prevalence, but OSAS most certainly exceeds than what is expected. Interestingly, in line with our study, a previous American study covering 5400 COVID-19 infected patients found that people with a pre-existing sleep disorders have more severe outcomes from COVID-19 [43]. However, another study conducted by Goldstein *et al*, on 572 adult patients hospitalized for COVID-19, reported no significant contribution of sleep disorders to outcomes of the illness [44].

In addition to cardio- and cerebrovascular disease and diabetes mellitus type 2, our data also suggests that autoimmune diseases may have some impact on the risk for COVID-19 (Table 1 and S1 Table). An interesting background in this respect are studies of MS, with differences in the outcome related to the choice of immunomodulating drugs [45, 46]. In our material, however, the presence of autoimmune disease and immunoactive therapy made no difference regarding the outcome of the infection, taken from comparison between severe versus non severe COVID-19 disease (ICU versus non- ICU patients). An impact by autoimmune disease has previously been reported [47], which has been suggested to be associated with glucocorticoid administration.

In addition, a study from the Queen Mary University in London [48] suggested that persons with a prior allergic disease, particularly asthma have a lower risk to develop severe COVID-19, perhaps because the expression of *ACE2* is lower in people with allergic asthma and allergic sensitization [39]. However, in our study, asthma, and allergic rhinitis stand up as a comorbidity with relatively high incidences (23% respective 16%) (Table 1). Earlier data has also suggested a higher rate of asthma in patients hospitalized for severe COVID-19 illness [49], although this data as well as our study does not specify whether the asthma is allergic. There are also other studies [50, 51] reporting none significant impact of respiratory allergy on severity of COVID-19.

The current study has several limitations. This is a regional study conducted in a relatively homogeneous cohort. This per se, together with a small number of patients limit our understanding of the true extensiveness of neurological problems associated with COVID-19. Additionally, the study cohort was collected during the very early pandemic when treatment regimen and knowledge of COVID-19 was limited which might have rendered this population particularly vulnerable for a more severe disease course. Despite limitations, our findings are quite well consistent and in line with previous reported neurological manifestations and comorbidities by other groups, and supports the conclusion that neurological manifestations are an important cause of COVID-19, and even suggested to be a primary feature of COVID-19 disease [52] and possibly a risk factor for mortality [53], despite the fact that mechanism behind neurological symptoms are still unknown, which needs to be further elucidated.

Conclusion

Neurological symptoms were found in 74% of the COVID-19 patients. Several risk factors in terms of co-morbidities, i.e., preceding, and concurrent diseases, were identified which gives an interesting background for further studies on the topic in order to optimizing care for COVID 19-patients in the future including identifying risk groups that should get appropriate attention. This study is planned for a long-term follow up, giving further opportunity to determine the impact of such risk factors in the long-term outcome as well as the odds for post COVID syndrome.

Supporting information

S1 Table. S1 Table shows the characteristics of patients with autoimmune disease, the disease and the treatment where applicable.

(DOCX)

S2 Table. S2 Table shows the characteristics of ICU versus non-ICU patients.

(DOCX)

Author Contributions

Conceptualization: Sara Haghighi.

Data curation: Anna Kristoffersson.

Funding acquisition: Sara Haghighi.

Methodology: Ellen Iacobaeus, Sara Haghighi.

Project administration: Anna Kristoffersson, Anne Eriksson, Sara Haghighi.

Supervision: Sara Haghighi.

Validation: Mats Fredrikson, Sara Haghighi.

Writing – review & editing: Doryaneh Ahmadpour, Yumin Huang-Link, Ellen Iacobaeus, Anne-Marie Landtblom, Sara Haghighi.

References

1. Drosten C, Kellam P, Memish ZA. Evidence for camel-to-human transmission of MERS coronavirus. *N Engl J Med*. 2014; 371(14):1359–60. <https://doi.org/10.1056/NEJMc1409847> PMID: 25271615
2. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. *Lancet*. 2003; 361(9366):1319–25. [https://doi.org/10.1016/s0140-6736\(03\)13077-2](https://doi.org/10.1016/s0140-6736(03)13077-2) PMID: 12711465
3. Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory syndrome. *N Engl J Med*. 2003; 349(25):2431–41. <https://doi.org/10.1056/NEJMra032498> PMID: 14681510
4. Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? *Clin Microbiol Infect*. 2020; 26(6):729–34. <https://doi.org/10.1016/j.cmi.2020.03.026> PMID: 32234451
5. Ahmadpour D, Ahmadpour P, Rostaing L. Impact of Circulating SARS-CoV-2 Mutant G614 on the COVID-19 Pandemic. *Iran J Kidney Dis*. 2020; 14(5):331–4. PMID: 32943587
6. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020; 579(7798):270–3. <https://doi.org/10.1038/s41586-020-2012-7> PMID: 32015507
7. Dixon BE, Wools-Kaloustian K, Fadel WF, Duszynski TJ, Yiannoutsos C, Halverson PK, et al. Symptoms and symptom clusters associated with SARS-CoV-2 infection in community-based populations: Results from a statewide epidemiological study. *medRxiv*. 2020. <https://doi.org/10.1101/2020.10.11.20210922> PMID: 33106813
8. Zoghi G, Moosavy SH, Yavarian S, HasaniAzad M, Khorrani F, Sharegi Brojeni M, et al. Gastrointestinal implications in COVID-19. *BMC Infect Dis*. 2021; 21(1):1135. <https://doi.org/10.1186/s12879-021-06824-y> PMID: 34736412
9. Guan WJ, Zhong NS. Clinical Characteristics of Covid-19 in China. Reply. *N Engl J Med*. 2020; 382(19):1861–2. <https://doi.org/10.1056/NEJMc2005203> PMID: 32220206
10. Huang B, Ling R, Cheng Y, Wen J, Dai Y, Huang W, et al. Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options. *Mol Ther Methods Clin Dev*. 2020; 18:367–75. <https://doi.org/10.1016/j.omtm.2020.06.013> PMID: 32665963
11. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and Multiorgan Response. *Curr Probl Cardiol*. 2020; 45(8):100618. <https://doi.org/10.1016/j.cpcardiol.2020.100618> PMID: 32439197

12. Tsai PH, Lai WY, Lin YY, Luo YH, Lin YT, Chen HK, et al. Clinical manifestation and disease progression in COVID-19 infection. *J Chin Med Assoc.* 2021; 84(1):3–8. <https://doi.org/10.1097/JCMA.000000000000463> PMID: 33230062
13. Gao M, Piernas C, Astbury NM, Hippisley-Cox J, O'Rahilly S, Aveyard P, et al. Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study. *Lancet Diabetes Endocrinol.* 2021; 9(6):350–9.
14. Ji W, Huh K, Kang M, Hong J, Bae GH, Lee R, et al. Effect of Underlying Comorbidities on the Infection and Severity of COVID-19 in Korea: a Nationwide Case-Control Study. *J Korean Med Sci.* 2020; 35(25): e237. <https://doi.org/10.3346/jkms.2020.35.e237> PMID: 32597048
15. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. *SN Compr Clin Med.* 2020; 2(8):1069–76. <https://doi.org/10.1007/s42399-020-00363-4> PMID: 32838147
16. Abdullahi A, Candan SA, Abba MA, Bello AH, Alshehri MA, Afamefuna Victor E, et al. Neurological and Musculoskeletal Features of COVID-19: A Systematic Review and Meta-Analysis. *Front Neurol.* 2020; 11:687. <https://doi.org/10.3389/fneur.2020.00687> PMID: 32676052
17. Favas TT, Dev P, Chaurasia RN, Chakravarty K, Mishra R, Joshi D, et al. Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions. *Neurol Sci.* 2020; 41(12):3437–70. <https://doi.org/10.1007/s10072-020-04801-y> PMID: 33089477
18. Misra S, Kolappa K, Prasad M, Radhakrishnan D, Thakur KT, Solomon T, et al. Frequency of Neurologic Manifestations in COVID-19: A Systematic Review and Meta-analysis. *Neurology.* 2021; 97(23): e2269–e81. <https://doi.org/10.1212/WNL.0000000000012930> PMID: 34635561
19. Liu K, Pan M, Xiao Z, Xu X. Neurological manifestations of the coronavirus (SARS-CoV-2) pandemic 2019–2020. *J Neurol Neurosurg Psychiatry.* 2020; 91(6):669–70. <https://doi.org/10.1136/jnnp-2020-323177> PMID: 32312873
20. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol.* 2020; 77(6):683–90. <https://doi.org/10.1001/jamaneurol.2020.1127> PMID: 32275288
21. Agarwal P, Ray S, Madan A, Tyson B. Neurological manifestations in 404 COVID-19 patients in Washington State. *J Neurol.* 2021; 268(3):770–2. <https://doi.org/10.1007/s00415-020-10087-z> PMID: 32761507
22. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic Features in Severe SARS-CoV-2 Infection. *N Engl J Med.* 2020; 382(23):2268–70. <https://doi.org/10.1056/NEJMc2008597> PMID: 32294339
23. Wenting A, Gruters A, van Os Y, Verstraeten S, Valentijn S, Ponds R, et al. COVID-19 Neurological Manifestations and Underlying Mechanisms: A Scoping Review. *Front Psychiatry.* 2020; 11:860. <https://doi.org/10.3389/fpsy.2020.00860> PMID: 32973590
24. Shehata GA, Lord KC, Grudzinski MC, Elsayed M, Abdelnaby R, Elshabrawy HA. Neurological Complications of COVID-19: Underlying Mechanisms and Management. *Int J Mol Sci.* 2021; 22(8). <https://doi.org/10.3390/ijms22084081> PMID: 33920904
25. Kim HK, Cho YJ, Lee SY. Neurological Manifestations in Patients with COVID-19: Experiences from the Central Infectious Diseases Hospital in South Korea. *J Clin Neurol.* 2021; 17(3):435–42. <https://doi.org/10.3988/jcn.2021.17.3.435> PMID: 34184452
26. Chou SH-Y, Beghi E, Helbok R, Moro E, Sampson J, Altamirano V, et al. Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19—A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. *JAMA Network Open.* 2021; 4(5):e2112131–e. <https://doi.org/10.1001/jamanetworkopen.2021.12131> PMID: 33974053
27. Frontera JA, Sabadia S, Lalchan R, Fang T, Flusty B, Millar-Vernetti P, et al. A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City. *Neurology.* 2021; 96(4):e575–e86. <https://doi.org/10.1212/WNL.0000000000010979> PMID: 33020166
28. Aljumaiah R, Alturaiki W, Alosaimi B. Confusion and Hallucination: A Case Report of an Unusual Presentation of COVID-19. *Case Rep Psychiatry.* 2021; 2021:3794019. <https://doi.org/10.1155/2021/3794019> PMID: 34984107
29. Mirfazeli FS, Sarabi-Jamab A, Jahanbakhshi A, Kordi A, Javadnia P, Shariat SV, et al. Neuropsychiatric manifestations of COVID-19 can be clustered in three distinct symptom categories. *Sci Rep.* 2020; 10(1):20957. <https://doi.org/10.1038/s41598-020-78050-6> PMID: 33262404
30. Clouden TA. Persistent Hallucinations in a 46-Year-Old Woman After COVID-19 Infection: A Case Report. *Cureus.* 2020; 12(12):e11993. <https://doi.org/10.7759/cureus.11993> PMID: 33437548

31. Nachtigall I, Bonsignore M, Thurmann P, Hohenstein S, Jozwiak K, Hauptmann M, et al. Sex Differences in Clinical Course and Intensive Care Unit Admission in a National Cohort of Hospitalized Patients with COVID-19. *J Clin Med*. 2021; 10(21).
32. Sawadogo W, Tsegaye M, Gizaw A, Adera T. Overweight and obesity as risk factors for COVID-19-associated hospitalisations and death: systematic review and meta-analysis. *BMJ Nutr Prev Health*. 2022; 5(1):10–8. <https://doi.org/10.1136/bmjnp-2021-000375> PMID: 35814718
33. Kompaniyets L, Goodman AB, Belay B, Freedman DS, Sucusky MS, Lange SJ, et al. Body Mass Index and Risk for COVID-19-Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death—United States, March–December 2020. *MMWR Morb Mortal Wkly Rep*. 2021; 70(10):355–61. <https://doi.org/10.15585/mmwr.mm7010e4> PMID: 33705371
34. Mubarik S, Liu X, Eshak ES, Liu K, Liu Q, Wang F, et al. The Association of Hypertension With the Severity of and Mortality From the COVID-19 in the Early Stage of the Epidemic in Wuhan, China: A Multicenter Retrospective Cohort Study. *Front Med (Lausanne)*. 2021; 8:623608. <https://doi.org/10.3389/fmed.2021.623608> PMID: 34055822
35. Chen J, Liu Y, Qin J, Ruan C, Zeng X, Xu A, et al. Hypertension as an independent risk factor for severity and mortality in patients with COVID-19: a retrospective study. *Postgraduate Medical Journal*. 2022; 98(1161):515–22. <https://doi.org/10.1136/postgradmedj-2021-140674> PMID: 34611036
36. Wang X, Zhang H, Du H, Ma R, Nan Y, Zhang T. Risk Factors for COVID-19 in Patients with Hypertension. *Can J Infect Dis Med Microbiol*. 2021; 2021:5515941. <https://doi.org/10.1155/2021/5515941> PMID: 34055114
37. Du Y, Zhou N, Zha W, Lv Y. Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: A meta-analysis. *Nutr Metab Cardiovasc Dis*. 2021; 31(3):745–55. <https://doi.org/10.1016/j.numecd.2020.12.009> PMID: 33549450
38. Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). *J Clin Med*. 2020; 9(3). <https://doi.org/10.3390/jcm9030841> PMID: 32244852
39. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O'Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. *J Allergy Clin Immunol*. 2020; 146(1):203–6 e3. <https://doi.org/10.1016/j.jaci.2020.04.009> PMID: 32333915
40. Wang Y, Yang Y, Ren L, Shao Y, Tao W, Dai XJ. Preexisting Mental Disorders Increase the Risk of COVID-19 Infection and Associated Mortality. *Front Public Health*. 2021; 9:684112. <https://doi.org/10.3389/fpubh.2021.684112> PMID: 34434913
41. Luo Z, Xue L, Ma L, Liu Z. Comorbid Anxiety and Depression and Related Factors Among Pregnant and Postpartum Chinese Women During the Coronavirus Disease 2019 Pandemic. *Front Psychol*. 2021; 12:701629. <https://doi.org/10.3389/fpsyg.2021.701629> PMID: 34733199
42. Zhao YJ, Jin Y, Rao WW, Li W, Zhao N, Cheung T, et al. The prevalence of psychiatric comorbidities during the SARS and COVID-19 epidemics: a systematic review and meta-analysis of observational studies. *J Affect Disord*. 2021; 287:145–57. <https://doi.org/10.1016/j.jad.2021.03.016> PMID: 33799032
43. Pena Orbea C, Wang L, Shah V, Jehi L, Milinovich A, Foldvary-Schaefer N, et al. Association of Sleep-Related Hypoxia With Risk of COVID-19 Hospitalizations and Mortality in a Large Integrated Health System. *JAMA Network Open*. 2021; 4(11):e2134241–e. <https://doi.org/10.1001/jamanetworkopen.2021.34241> PMID: 34757409
44. Goldstein CA, Rizvydeen M, Conroy DA, O'Brien LM, Gupta G, Somers EC, et al. The prevalence and impact of pre-existing sleep disorder diagnoses and objective sleep parameters in patients hospitalized for COVID-19. *J Clin Sleep Med*. 2021; 17(5):1039–50. <https://doi.org/10.5664/jcsm.9132> PMID: 33560208
45. Landtblom AM, Berntsson SG, Bostrom I, Iacobaeus E. Multiple sclerosis and COVID-19: The Swedish experience. *Acta Neurol Scand*. 2021; 144(3):229–35. <https://doi.org/10.1111/ane.13453> PMID: 34028810
46. Iacobaeus E, Bostrom I, Zhukovsky C, Berntsson S, Landtblom A. THE RISK OF COVID-19 SEVERITY IN PATIENTS WITH MS APPEARS TO BE ASSOCIATED WITH IMMUNOTHERAPY. *Health Risk Analysis*. 2021; 3:141–5.
47. Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. *Ann Rheum Dis*. 2021; 80(3):384–91. <https://doi.org/10.1136/annrheumdis-2020-218946> PMID: 33051220
48. Holt H, Talaei M, Greenig M, Zenner D, Symons J, Relton C, et al. Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK). *Thorax*. 2021. <https://doi.org/10.1136/thoraxjnl-2021-217487> PMID: 34848555
49. Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019—

- COVID-NET, 14 States, March 1–30, 2020. *MMWR Morb Mortal Wkly Rep.* 2020; 69(15):458–64. <https://doi.org/10.15585/mmwr.mm6915e3> PMID: 32298251
50. Guvey A. How does allergic rhinitis impact the severity of COVID-19?: a case-control study. *Eur Arch Otorhinolaryngol.* 2021; 278(11):4367–71. <https://doi.org/10.1007/s00405-021-06836-z> PMID: 33932179
 51. El Shahawy AA, Oladimeji KE, Hamdallah A, Saidani A, Abd-Rabu R, Dahman NBH. Prognosis of COVID-19 in respiratory allergy: a systematic review and meta-analysis. *The Egyptian Journal of Bronchology.* 2022; 16(1):12.
 52. Johansson A, Mohamed MS, Moulin TC, Schioth HB. Neurological manifestations of COVID-19: A comprehensive literature review and discussion of mechanisms. *J Neuroimmunol.* 2021; 358:577658. <https://doi.org/10.1016/j.jneuroim.2021.577658> PMID: 34304141
 53. Carlos CR, Gerardo MM, Jaime OG, Isauro GHL, Dios APJ. Prevalence of neurological manifestations in COVID-19 and their association with mortality. *Neurology perspectives.* 2021; 1(1):11–6.